A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Alzheimer's disease appears to damage the brain in two phases, and treatment before the latter stage, when "suddenly things ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...